We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.1B
1-Year Est. Return 799.93%
This Fund
S&P 500
This Quarter Est. Return
+17.48%
1 Year Est. Return
+799.93%
3 Year Est. Return
+7,491.17%
5 Year Est. Return
+13,644.18%
10 Year Est. Return
+154,603.62%
AUM
$1.1B
AUM Growth
-$108M
Cap. Flow
-$186M
Cap. Flow %
-16.99%
Top 10 Hldgs %
52.4%
Holding
53
New
7
Increased
6
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$29.3M
2
AVBP icon
ArriVent BioPharma
AVBP
+$23.5M
3
ABVX
Abivax
ABVX
+$19.8M
4
ACHV icon
Achieve Life Sciences
ACHV
+$13.1M
5
EDIT icon
Editas Medicine
EDIT
+$10.4M

Top Sells

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$115M
2
TERN
Terns Pharmaceuticals
TERN
+$70.4M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$21.5M
4
TNGX icon
Tango Therapeutics
TNGX
+$19.2M
5
MANE
Veradermics Inc
MANE
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANTX icon
26
AN2 Therapeutics
ANTX
$202M
$15.3M 1.39%
3,153,640
– –
EDIT icon
27
Editas Medicine
EDIT
$416M
$11.5M 1.05%
+3,555,250
New +$10.4M
GERN icon
28
Geron
GERN
$829M
$11.1M 1.01%
8,671,797
– –
ODTX
29
Odyssey Therapeutics
ODTX
$1.11B
$10.8M 0.98%
+575,000
New +$10.1M
EPRX
30
Eupraxia Pharmaceuticals
EPRX
$535M
$8.92M 0.81%
1,350,000
– –
OKUR
31
OnKure Therapeutics
OKUR
$117M
$8.79M 0.8%
1,927,710
– –
OLMA icon
32
Olema Pharmaceuticals
OLMA
$851M
$8.4M 0.77%
671,843
– –
MNPR icon
33
Monopar Therapeutics
MNPR
$681M
$8.38M 0.77%
90,500
– –
AURA icon
34
Aura Biosciences
AURA
$698M
$8.28M 0.76%
+1,166,667
New +$8.35M
SRZN icon
35
Surrozen
SRZN
$199M
$6.75M 0.62%
260,000
– –
ALXO icon
36
ALX Oncology
ALXO
$243M
$6.59M 0.6%
3,184,713
– –
MSLE
37
Satellos Bioscience
MSLE
$197M
$6.33M 0.58%
813,666
– –
AVTX icon
38
Avalo Therapeutics
AVTX
$889M
$5.08M 0.46%
+275,000
New +$4.35M
PEPG icon
39
PepGen
PEPG
$201M
$4.18M 0.38%
2,325,000
– –
VALN
40
Valneva
VALN
$623M
$3.99M 0.36%
+763,199
New +$4.34M
SERA icon
41
Sera Prognostics
SERA
$79.7M
$3M 0.27%
1,650,440
– –
UNCY icon
42
Unicycive Therapeutics
UNCY
$133M
$2.58M 0.24%
550,000
-1,239,916
-69% -$9.15M
TIL icon
43
Instil Bio
TIL
$48.7M
$2.25M 0.21%
292,743
– –
INM icon
44
InMed Pharmaceuticals
INM
$7.03M
$1.24M 0.11%
+798,377
New +$882K
BOLT icon
45
Bolt Biotherapeutics
BOLT
$6.99M
$279K 0.03%
72,414
– –
KTTA icon
46
Pasithea Therapeutics
KTTA
$16.4M
$240K 0.02%
465,471
-1,634,529
-78% -$1.12M
DTIL icon
47
Precision BioSciences
DTIL
$183M
$36.7K ﹤0.01%
4,675
– –
CMPS
48
Compass Pathways
CMPS
$1.91B
– –
-200,000
Closed -$1.11M
COGT icon
49
Cogent Biosciences
COGT
$5.65B
– –
-422,300
Closed -$16.3M
SLNO
50
DELISTED
Soleno Therapeutics
SLNO
– –
-294,909
Closed -$9.87M
1
2
3

Similar funds

JVBC
J.V. Bruni & Co Colorado Springs, Colorado $1.1B AUM 38.56% 1-Year Est. Return
WAM
Wellesley Asset Management Portsmouth, New Hampshire $1.1B AUM 0% 1-Year Est. Return
RDWM
Red Door Wealth Management Memphis, Tennessee $1.1B AUM 31.77% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return
GA
Goldstein Advisors Madison, Wisconsin $1.09B AUM 23.69% 1-Year Est. Return
BMM
Berkshire Money Management Dalton, Massachusetts $1.09B AUM 20.64% 1-Year Est. Return
TLIC
Taiyo Life Insurance Company Chuo-Ku, Tokyo, Japan $1.09B AUM 26.68% 1-Year Est. Return
KI
Koch Inc Wichita, Kansas $1.09B AUM 59.79% 1-Year Est. Return

Vivo Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Vivo Capital held 53 positions worth $1.1B, down 9% from $1.2B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Vivo Capital withdrew a net $186M in Q2 2026, closing 6 positions and reducing 8 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $70.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Achieve Life Sciences worth $18M.

  • Vivo Capital's largest Q2 2026 buy was Achieve Life Sciences: 2,751,032 shares worth $18M.
  • Vivo Capital added most to Tenax Therapeutics in Q2 2026, an estimated $29.3M increase.
  • Vivo Capital's biggest Q2 2026 reduction was Erasca, cutting an estimated $115M.
  • Vivo Capital fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $70.4M.
  • Vivo Capital's ten largest holdings make up 52% of its $1.1B portfolio in Q2 2026.
  • Vivo Capital opened 7 new positions and closed 6 in Q2 2026.
  • Vivo Capital's portfolio value fell 9% quarter-over-quarter to $1.1B.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.